Palopegteriparatide
Yorvipath (palopegteriparatide) is a prescription medication injected under the skin to treat osteoporosis in certain adults. It works by mimicking parathyroid hormone to help build bone strength. Available in solution form with doses like 0.168 mg or 0.42 mg per cartridge. Manufactured by Ascendis Pharma, Endocrinology, Inc. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Yorvipath (palopegteriparatide) is a prescription medication injected under the skin to treat osteoporosis in certain adults. It works by mimicking parathyroid hormone to help build bone strength. Available in solution form with doses like 0.168 mg or 0.42 mg per cartridge. Manufactured by Ascendis Pharma, Endocrinology, Inc. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Palopegteriparatide",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Palopegteriparatide — ANDA 216490 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216490"
}
]
|
| identifier | ANDA216490 |
| issued | 2016-09-16 |
| keyword |
[
"drug-information",
"health-care",
"medications",
"prescription-drugs",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Palopegteriparatide |
